Skip to Main Content
Advertisement intended for health care professionals
Close
ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology
The Hematologist
International
Blood Chinese Edition
Blood Italian Edition
Blood Latin America Edition
Blood Spanish Edition
ASH
ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store
Cart
User Tools Dropdown
Cart
Sign In
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
All Journals
Blood
Search
Toggle Menu
Menu
Issues
Current Issue
All Issues
First edition
Abstracts
2024 Annual Meeting
2024 Late Breaking
2023 Annual Meeting
2023 Late Breaking
2022 Annual Meeting
2022 Late Breaking
2021 Annual Meeting
2020 Annual Meeting
2020 Late Breaking
All Meeting Abstracts
Collections
Collections
Special Collections
Blood Podcast
Multimedia
Alerts
Author Center
Submit
Author Guide
Style Guide
Why Submit to Blood?
About
About Blood
Editorial Board
Publications Staff
Subscriptions
Public Access
Copyright
Alerts
Blood Classifieds
Skip Nav Destination
Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase
Blood
(2023) 142 (Supplement 1): 328.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
Advertisement intended for health care professionals
close advertisement
